VivoSim Labs, Inc. (Nasdaq: VIVS) received a formal deficiency notice from Nasdaq's Listing Qualifications Staff on July 20, 2026, after the San Diego biotech's Form 10-K for the year ended March 31, 2026 showed stockholders' equity of negative $1,099,000, well below Nasdaq's $2.5 million minimum under Listing Rule 5550(b)(1). The company simultaneously disclosed that its equity had already crossed back above that threshold, the result of three separate capital events that closed in rapid succession before the notice arrived.
The deficiency and its compliance clock
Nasdaq's rule allows two remediation paths. VivoSim has until September 3, 2026 (45 calendar days from the notice date) to submit a compliance plan. If Nasdaq accepts that plan, the company could receive up to 180 calendar days from July 20, 2026, extending the window to January 16, 2027, to demonstrate sustained compliance. Failure to satisfy Nasdaq at either stage triggers an appeal right before a Nasdaq hearings panel. The notice carries no immediate trading consequence; VIVS remains listed on the Nasdaq Capital Market.
What changed the balance sheet
Three transactions did the work. A $5.0 million milestone payment arrived from Eli Lilly and Company in July 2026, tied to a development milestone connected to VivoSim's sale of its FXR Asset in March 2025. Separately, between July 15 and July 17, 2026, approximately 3,370,827 of the 3,947,369 common stock warrants issued in connection with a public offering that closed April 1, 2026 were exercised, generating roughly $5.1 million in additional stockholders' equity and converting into 6,820,000 shares of common stock. That warrant block had carried a liability of approximately $5.7 million on VivoSim's books at the time of the 10-K filing.
The third transaction was a private placement that closed July 17, 2026, under a Securities Purchase Agreement signed July 16, 2026 with a single accredited institutional investor. VivoSim sold pre-funded warrants and accompanying common warrants, each covering up to 4,705,883 shares, at a combined price of $0.85 per share, raising gross proceeds of approximately $4.0 million before placement agent fees.
The counterargument
The counterargument deserves a fair hearing. Nasdaq's deficiency test is backward-looking, anchored to the March 31, 2026 balance sheet. Whether the equity rebuilt through these transactions holds above $2.5 million depends on how warrant liabilities are marked going forward, on the pace of operating cash burn, and on whether the Eli Lilly milestone represents a durable income source or a one-time receipt from an asset already divested. VivoSim itself acknowledges it cannot assure Nasdaq will accept a compliance plan or that the company can maintain any Nasdaq requirement going forward.
The line to watch
On balance, the equity math appears to have moved in VivoSim's favor before the compliance clock even started running. The line to watch is the September 3, 2026 plan submission. If Nasdaq pushes back, the question shifts from whether VIVS survives the notice to whether a company now carrying 12,057,789 shares of common stock outstanding can hold equity above $2.5 million through a remediation window that runs to January 16, 2027.